(Yicai) March 23 -- For more than a decade, the promise of artificial intelligence in biotechnology has centered on discovery. AI would identify new drug targets, generate molecules, and compress years of chemistry into weeks. Those promises were not wrong, but aimed at the wrong battlefield.

The next decisive frontier for AI in life sciences is not discovery, but clinical trial design, where uncertainty is highest, capital is most fragile, and a single decision can determine whether a therapy reaches patients or disappears entirely.

In 2026, the organizations that lead will not simply move faster. They will move faster without sacrificing scientific rigor.

The Real Leverage Point in Drug Development

Drug discovery captures imagination. Clinical development determines outcomes.

The pharmaceutical industry spends more than USD300 billion on research and development each year, yet bringing a therapy to market still takes roughly a decade, and the majority of drug candidates fail during clinical trials.

The reason is simple: clinical development is where scientific theory meets operational reality.

Nowhere is this tension more visible than in Phase II proof-of-concept trials, which force teams to make consequential decisions under deep uncertainty, choosing endpoints, defining control strategies, estimating sample size, and locking statistical analysis plans. Once patient enrollment begins, these decisions become extremely difficult to change.

For small biotech companies, Phase II is often a defining moment. Limited patients. Limited capital. Limited statistical resources. The design decisions made at this stage frequently determine whether a program secures funding, attracts a pharmaceutical partner, or stops altogether.

Clinical trial design has therefore become an emerging competitive frontier, one where scientific credibility, investor confidence, and regulatory readiness intersect.

Why Good Science Still Fails?

Biotechnology failures are often attributed to biological complexity. Biology is indeed hard. 

However, another factor is frequently overlooked. Programs do not fail only because the science is weak, but because early assumptions, made under uncertainty, gradually harden into expensive commitments.

Clinical development history is filled with examples of therapies that showed promising signals but failed to reach statistical significance. In such cases, patients may have benefited, but the evidence was insufficient for regulatory approval. The program ends and the drug never reaches the market.

This reality has pushed regulators, sponsors, and investors toward a common goal: improving decision quality, not simply accelerating execution.

AI's Real Role as Decision Infrastructure

The most productive way to understand AI in clinical development is not automation. It is a decision infrastructure.

AI should not replace scientific judgment, nor function as a black box. Its value lies in revealing assumptions, quantifying uncertainty, and enabling exploration of design choices before real patients and real capital are committed.

In other words, AI improves the quality of decisions, not simply the speed of calculations.

Three decision points illustrate where this shift is becoming most visible.

1. Sample Size: The Most Expensive Assumption

Sample size appears to be a statistical question. In reality, it is also a strategic one.

A trial that is too small may fail to detect a meaningful treatment effect, while one that is too large consumes time, capital, and operational capacity. Both outcomes can destroy value.

AI changes this calculation by enabling large-scale scenario simulation before trial launch. Instead of relying on a narrow set of assumptions, teams can explore thousands of potential scenarios, testing how sensitive outcomes are to changes in effect size, variance, or patient heterogeneity.

This approach provides leaders with a clearer view of the probability of success and potential failure modes.

Adaptive techniques such as sample size re-estimation are also attracting renewed attention when implemented with strict governance and statistical discipline.

2. Variability: the Hidden Enemy of Small Trials

In small studies, variability can overwhelm the signal.

Even with randomization, small sample sizes can produce imbalanced baseline characteristics across treatment arms. When that happens, the interpretation of trial results becomes more difficult and the risk of false-negative outcomes increases.

One way to understand the challenge is through a simple analogy. Instead of always trying to increase statistical power by enrolling more patients, the field increasingly needs "noise-canceling" strategies, reducing variability through careful covariate adjustment.

Covariate adjustment has long been recognized as one such approach. AI expands its potential by helping identify which patient characteristics meaningfully influence outcomes and which do not. By analyzing broader datasets and exploring complex relationships, AI can assist researchers in constructing more precise covariate strategies.

Regulatory agencies, including the US' Food and Drug Administration, have increasingly emphasized the importance of careful pre-specification and scientific justification in this area.

3. Control Strategy and Synthetic Data

Randomized controlled trials remain the gold standard, yet they are not always feasible. Rare diseases, ethical considerations, and patient burden can make traditional randomization difficult. In these cases, sponsors may explore historical controls or synthetic control arms to improve trial feasibility.

Such approaches are promising, but come with significant credibility requirements.

Synthetic patient strategies must meet regulatory standards for evidence generation, with clear data provenance, transparent methodology, pre-specified analytical frameworks, and rigorous validation within defined contexts of use. Without these elements, synthetic strategies are unlikely to gain regulatory acceptance.

Synthetic data cannot be treated as a shortcut. It must be treated as evidence engineering.

Regulatory Reality

One question consistently arises among biotech founders and investors: Will regulators accept AI-enabled approaches?

The answer is more nuanced than a simple yes or no. It depends less on the technology itself and more on how it is used. Regulators evaluate new methodologies according to three principles: credibility, transparency, and context of use.

Recent guidance has emphasized improved statistical efficiency, including covariate adjustment and modeling approaches. Draft frameworks for AI-assisted decision-making also suggest increasing openness, provided that methods meet rigorous scientific standards.

Across the global regulatory landscape, a broader concept is emerging: good AI practice in drug development.

Why Clinical Trial Design Matters?

Clinical development remains the most failure-prone and capital-intensive phase of pharmaceutical R&D. Industry data consistently shows low overall success rates, with Phase II representing one of the most challenging development stages.

This is precisely why clinical trial design has become such a critical leverage point. In a low-probability environment, even modest improvements in early decision quality can compound into meaningful improvements in success rates.

Operating Principle for 2026

AI will continue to accelerate clinical development, but speed alone is not the goal.

Speed without discipline can destroy value as easily as it creates it.

Clinical trial decisions involve trade-offs between scientific evidence, operational feasibility, regulatory expectations, and investor priorities, with these decisions requiring leadership judgment.

AI can illuminate the landscape, but cannot replace accountability.

For biotech leaders planning the next generation of trials, the most practical advice is simple: use AI early, while assumptions can still be challenged, designs can still evolve, and rigor can be embedded into the foundation of the program.

That is where the real leverage lies.

The author of this article is Xiaomai Zhang, chief marketing officer at HopeAI and a columnist writing on the intersection of AI, statistics, and clinical development strategy. Xiaomai's views are informed by cross-sector clinical, statistical, and investment perspectives, as well as insights from recent discussions recorded for the firm's HopeTalk interview series.

Editor: Martin Kadiev